Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer

[cafead]

via Genentech, a Roche company, announced that the Phase III IMagyn050 trial of Tecentriq (atezolizumab) and Avastin (bevacizumab), paclitaxel and carboplatin did not hit the primary endpoint of progression-free survival (PFS) for frontline newly-diagnosed advanced ovarian cancer.

article source